摘要:
A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
摘要:
A molecular marker for detecting a cancer stem cell in a cell mass which is a subject of interest, wherein the molecular marker can be detected in a cancer stem cell contained in the subject of interest but cannot be detected in a normal cell and a cancer cell that is different from a cancer stem cell; a method for determining the presence or absence of a cancer stem cell in a subject of interest by using the molecular marker as an measure; a kit for determining the presence or absence of a cancer stem cell, which comprises at least a reagent for detecting the molecular marker; a polypeptide encoded by the molecular marker; an antibody capable of recognizing an epitope of an expression product of a gene derived from the molecular marker; a nucleic acid capable of inhibiting the expression of the molecular marker; and a nucleic acid vaccine comprising a gene derived from the molecular marker.
摘要:
The invention relates to novel tumor antigen proteins and peptides derived therefrom and use of the same in the filed of cancer immunity. Specifically, the inventions relates to a peptide which comprises a partial peptide derived from Lengsin, BJ-TSA-9, C20orf42, BUB1, C10orf3 or HIFPH3 and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier.
摘要:
The present invention relates to a peptide which comprises a partial peptide derived from AMACR and is capable of binding to an HLA antigen and is recognized by a CTL, and a pharmaceutical composition comprising the peptide and a pharmaceutically acceptable carrier, and the like.
摘要:
The present invention provides a partial peptide consisting of 8-11 contiguous amino acids in the amino acid sequence of livin set forth in SEQ ID NO: 1, which binds to HLA-A24 antigen and is recognized by cytotoxic T cells (CTLs), a polynucleotide encoding the peptide, and cancer vaccine comprising the peptide or the polynucleotide.
摘要翻译:本发明提供由SEQ ID NO:1所示的livin氨基酸序列中的8-11个连续氨基酸组成的部分肽,其结合HLA-A24抗原并被细胞毒性T细胞(CTLs)识别, 编码该肽的多核苷酸,以及包含该肽或该多核苷酸的癌症疫苗。
摘要:
A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.
摘要:
[Technical Problem] The present invention provides an enhancer of cellular immunity, and provides applications to carcinogenesis or preventive therapy against cancer recurrence, immunotherapy for cancer, treatment for pathogenic microorganism infection, and the like.[Technical Solution] The present invention comprises the substance having an inhibitory activity of histone deacetylase (HDAC) as an active component.
摘要:
[PROBLEMS] To provide a monoclonal antibody simultaneously detectable the expression of all three kinds of HLA-A, HLA-B and HLA-C heavy chain proteins composing human class I leukocyte antigens (HLA class I) in denatured human tissue samples fixed by formalin and the like.[MEANS FOR SOLVING THE PROBLEMS] It was discovered that injection of denatured recombinant HILA-A*2402 heavy chain proteins to mouse for immunization led to establish HLA class I-specific antibody binding all of denatured HLA-A, B and C. The present invention is a monoclonal antibody specifically binding HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens, wherein said monoclonal antibody is produced by hybridomas (FERM AP-20454) and bound specifically HLA-A, HLA-B and HLA-C heavy chains composing denatured human class I antigens. Furthermore, the present invention is a test reagent for examining denatured human class I leukocyte antigens containing the monoclonal antibody as a major component.
摘要:
A tumor antigen gene is identified by screening a cDNA library derived from a gastric cancer cell line that can induce gastric cancer antigen specific cytotoxic T cell (CTL) by means of hybridization and PCR utilizing an amino acid sequence of peptide fragment of a known gastric cancer antigen protein, introducing a selected cDNA clone into a cell of gastric cancer cell line that cannot induce gastric cancer antigen specific CTL so that the clone should be expressed in the cell, and selecting a transgenic cell that has acquired the ability to induce CTL. According to the present invention, there are provided a protein capable of inducing immune response against human gastric cancer, DNA encoding the protein, as well as vaccine for treatment and prevention of human gastric cancer, and agent for treatment and prevention of human gastric cancer.